Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib plus endocrine therapy with ovarian suppression versus docetaxel plus capecitabine in premenopausal HR-positive/HER2-negative recurrent or metastatic breast cancer
ChiCTR2000039242Phase 2Recruiting
- Sponsor
- The Second Affiliated Hospital of Dalian Medical University
- Start
- Nov 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of palbociclib, fulvestrant, goserelin, leuprolide, docetaxel and 1 more in breast cancer (2 arms), sponsored by The Second Affiliated Hospital of Dalian Medical University. Primary endpoint: Progression-free survival. Started Nov 2020; status: recruiting.
02
Drugs
palbociclibfulvestrantgoserelinleuprolidedocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2000039242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039242.